A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/20/2018
Start Date:August 2016
End Date:April 2020
Contact:Array BioPharma, Inc.
Email:clinicaltrials@arraybiopharma.com
Phone:303-381-6604

Use our guide to learn which trials are right for you!

A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in
adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the
efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors
that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant
ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).

ARRY-382 is an inhibitor of CSF1R (colony-stimulating factor-1 receptor).

Each phase of the study consists of a 28-day screening period; 21-day treatment cycles with
the combination of ARRY-382 and pembrolizumab until disease progression as determined by the
Investigator, unacceptable toxicity, withdrawal of consent, or death (or other
discontinuation criteria are met), and a 30-day safety follow-up period. Patients in all
cohorts/phases will be monitored for overall survival (OS) until 1 year after the date of the
last patient's first visit.

Key Inclusion Criteria

All Study Parts:

- Diagnosis of cancer that has been histologically or cytologically confirmed

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

Part A (1 of the following):

- Ovarian cancer, triple-negative breast cancer, head and neck squamous cell cancer,
bladder cancer, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, or
gastric cancer that is measurable or evaluable, nonmeasurable as defined by RECIST
v1.1 and meets 1 of the following criteria:

- is refractory to standard of care

- no standard therapy available

- patient refuses standard therapy

- Advanced, unresectable, or metastatic melanoma with or without prior treatment and
measurable or evaluable, nonmeasurable disease as defined by RECIST v1.1

- Advanced/metastatic PD-L1-positive NSCLC (defined as a tumor proportion score [TPS] ≥
50%) with measurable or evaluable, non-measurable disease as defined by RECIST v1.1 (1
of the following):

- 1) No prior systemic chemotherapy if tumor does not have EGFR or ALK genomic
aberrations

- 2) Disease progression on or after platinum-containing chemotherapy;

- 3) If tumor has EGFR or ALK genomic aberrations, disease progression on an
FDA-approved therapy for EGFR or ALK genomic tumor aberrations

Phase 2 (1 of the following):

- Advanced/metastatic solid tumor with PD as defined by RECIST 1.1 or irRC on an
anti-PD-1- or anti-PD-L1-containing regimen as their most recent prior therapy

- Advanced/metastatic epithelial ovarian cancer, peritoneal cancer or tubal cancer with
measurable disease as defined by RECIST 1.1, that had progressed within 6 months of
completing ≥ 4 cycles of platinum-based therapy

- Advanced/metastatic PDA that is locally advanced, unresectable or metastatic with
measurable disease as defined by RECIST v1.1 in patients who have received at least
one prior line of systemic therapy for their disease

Key Exclusion Criteria

1. Prior treatment as follows:

- Part A: an immune CPI (e.g., PD-1, PD-L1, or cytotoxic T-lymphocyte antigen 4
[CTLA-4] inhibitor).

NOTE: For patients with melanoma, prior treatment with ipilimumab is allowed if it was
administered as adjuvant therapy and treatment was completed at least 3 months prior
to enrollment.

- Phase 2:

- A CSF-1R inhibitor or CSF-1 (or MCSF) inhibitor.

- prOVCA and PDA patients only: an immune CPI (e.g., PD-1, PD-L1, or CTLA-4
inhibitor)

2. Symptomatic brain metastasis at screening

3. Active autoimmune disease, documented history of autoimmune syndrome or disease, or a
chronic medical condition that requires chronic steroid therapy or immunosuppressive
medication

4. History of pneumonitis or interstitial lung disease

5. Severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
that may increase the risk associated with study participation or study drug
administration or that may interfere with the interpretation of study results and, in
the judgment of the Investigator, would make the patient an inappropriate candidate
for the study

6. Ocular melanoma
We found this trial at
13
sites
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Justin Gainor, MD
Phone: 617-724-4000
?
mi
from
Boston, MA
Click here to add this to my saved trials
1871 SE Tiffany Ave # 100
Port Saint Lucie, Florida 34952
Principal Investigator: Seth Rosen, MD
Phone: 772-408-5158
?
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Karl Lewis, M.D.
Phone: 720-848-0668
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Charles L Cowey, MD
Phone: 214-370-1000
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Amy Weise, D.O.
Phone: 313-576-8387
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Diane Hershock, MD
Phone: 717-531-1003
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Lafayette, Indiana
Principal Investigator: Wael A. Harb, MD
Phone: 765-446-5111
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Jonathan Goldman, MD
Phone: 310-829-5471
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Principal Investigator: Melissa Johnson, MD
Phone: 877-691-7274
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
640 Jackson Street
Saint Paul, Minnesota 55101
651-254-3456
Principal Investigator: Arkadiusz Dudek, M.D.
Phone: 651-254-1698
Regions Hospital Established in 1872, Regions Hospital is a private, not-for-profit organization. The hospital provides...
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Salt Lake City, Utah 84106
Principal Investigator: Justin Call, MD
Phone: 801-281-6864
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
7979 Wurzbach Road
San Antonio, Texas 78229
Principal Investigator: John Sarantopolous, MD
Phone: 210-450-5798
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Jorge Chaves, MD
Phone: 253-396-5334
?
mi
from
Tacoma, WA
Click here to add this to my saved trials